MB Therapeutics

What MB Therapeutics does

MB Therapeutics, founded in 2023 and headquartered in Montpellier, France, develops and commercializes a turnkey pharmaceutical 3D printing platform called MED-U Prod for the on-demand production of personalized medicines at hospital and compounding pharmacies. The core technology combines a GMP-compliant industrial 3D printer, proprietary pharmaceutical software, qualification files, and the company's own proprietary pharmaceutical ink cartridges that integrate active ingredients and excipients, enabling precise dosage customization, combination of multiple active ingredients in a single polypill, and novel galenic forms such as dispersible and orodispersible tablets targeted primarily at pediatric and geriatric populations. The company operates its own GMP-certified pharmaceutical establishment for ink production and is qualified under BPF standards inspected by ANSM, FDA, and ANVISA.

The company sells its solution via direct B2B sales to hospital pharmacy departments (CHUs), compounding pharmacies, and pharmaceutical industry clients for clinical trial applications, with multi-year enterprise contracts. Revenue streams include hardware (printer sales), consumables (proprietary ink cartridges), software, qualification documentation, and ongoing support/training/maintenance services. Named deployments include CHU de Nîmes (host site for the Unité de Production des Médicaments) and CHU d'Angers (first commercial deployment in 2026), with a pilot pharmacy program planned for 2026 and early international expansion signals toward Germany.

MB Therapeutics is a venture-backed private spin-off from a collaboration between Lynxter (industrial 3D printer manufacturer) and CHU de Nîmes, co-founded by Dr. Stéphane Roulon (CEO, engineer) and Dr. Ian Soulairol (CTO, hospital pharmacist). The company has assembled a senior leadership team including a COO with 20+ years at Ipsen/MedinCell/Skyepharma, a CBO ex-Fareva for international expansion, and a Responsible Pharmacist/CQO. Total funding raised includes a €2M seed round in February 2025, a €500K France 2030 regionalized innovation grant, and earlier non-dilutive grants (French Tech Emergence, Créalia). The team comprises 1-10 employees, with the company operating from new premises featuring R&D labs and a future GMP cleanroom for in-house ink manufacturing.

Name

MB Therapeutics

Legal name

MB Therapeutics

Website

https://mb-therapeutics.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

11–50 employees

Short description

MB Therapeutics is a Montpellier-based pharmaceutical 3D printing company that sells a turnkey GMP-compliant system (MED-U Prod) with proprietary ink cartridges to hospital pharmacies, compounding pharmacies, and pharmaceutical companies for on-demand production of personalized medicines.

Ownership category

akta.pro rank

Product category

Pharmaceutical 3D Printing Equipment

NAICS

Pharmaceutical Preparation Manufacturing (325412), Surgical and Medical Instrument Manufacturing (339112), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)

SIC

Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)

akta.pro secondary industries

Medication Therapy Management (MTM) & Clinical Pharmacy Services Tools (HLACAKAH), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)

Keywords

• Pharmaceutical 3D printing
• Personalized medicine manufacturing
• GMP-compliant drug production
• Hospital pharmacy automation
• Pharmaceutical ink formulation

Headquarters

HQ city

Montpellier

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. 3D Printing Equipment Sales: Sale of pharmaceutical 3D printers and associated hardware to pharmacies and hospitals
2. Pharmaceutical Inks: Proprietary pharmaceutical ink cartridges and formulations for 3D printing of medications
3. Software and Qualification Services: Pharmaceutical software, qualification files, and support/training/maintenance services

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

MB Therapeutics develops and sells the MED-U Prod turnkey solution for automated production of personalized medicines through pharmaceutical 3D printing. The offering bundles an industrial-grade GMP-compliant pharmaceutical 3D printer, proprietary pharmaceutical software, qualification files for regulatory compliance, proprietary pharmaceutical inks (cartridges), and ongoing support, training, and maintenance services. Target customers are hospital pharmacies, compounding pharmacies, and pharmaceutical industry clients producing customized dosage forms.

Product overview

MB Therapeutics offers a unified product portfolio centered on pharmaceutical 3D printing for personalized medicine. The core offering is MED-U Prod, a turnkey solution combining industrial-grade pharmaceutical 3D printer hardware, proprietary pharmaceutical software, and proprietary pharmaceutical inks/cartridges. This system is complemented by formulation development services for creating printable drug compositions, qualification files for regulatory compliance, and ongoing support, training, and maintenance. The company develops its own GMP-certified pharmaceutical inks in-house, allowing precise dosage control and customized drug forms. Target markets include pharmacies, hospital pharmacies (CHUs), and the pharmaceutical industry.

Differentiator

Problem solved

Functional benefit

Products and services

• MED-U Prod A turnkey solution for automated production of personalized medicines through pharmaceutical 3D printing, enabling dosage customization, customized drug forms, and combination of multiple active ingredients in a single medication. Includes a GMP-compliant pharmaceutical 3D printer, software, qualification files, and support/maintenance. Designed for hospital pharmacies, compounding pharmacies, and pharmaceutical industry clients.
• Pharmaceutical 3D Printer Industrial-grade 3D printer designed for pharmaceutical manufacturing, capable of producing personalized oral forms with GMP compliance. Targeted at hospital pharmacies and compounding pharmacies for on-site personalized drug production.
• Pharmaceutical Software GMP pharmaceutical software used to control the pharmaceutical 3D printer and manage production of personalized medications. Sold as part of the MED-U Prod solution to hospital and compounding pharmacies.
• Qualification Files Regulatory documentation and qualification files for producing personalized oral forms with the pharmaceutical 3D printer, ensuring compliance with pharmaceutical standards. Targeted at pharmacies needing regulatory clearance for on-site drug production.
• Support, Training and Maintenance Customer support, expert training, commissioning, and maintenance services for pharmaceutical 3D printing operations. Provided to hospital and compounding pharmacy customers to achieve full proficiency with the system.
• Formulation Development Development of pharmaceutical formulations and pharmaceutical inks for 3D printing, including printable drug compositions with precise dosage control. Offered to pharmaceutical companies and research partners evaluating molecule printability.
• Proprietary Pharmaceutical Inks (Cartridges) Proprietary pharmaceutical ink cartridges integrating active ingredients and excipients for personalized medication production via 3D printing. Enables precise dosage adjustment and new galenic functionalities. GMP-certified production planned at MB Therapeutics' Montpellier facility.

Quantifiable outcome

• 40% of parents make administration errors with children's medications
• +2 more outcomes

Named customers6 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• CHU d'AngerscoreStrategic or Co-development Partner · 1 April 2026First deployment of MB Therapeutics' 3D printing solution at hospital pharmacy. Includes commissioning, expert training, and hands-on support for hospital pharmacists to achieve full proficiency with the system.
• CHU de NîmescoreStrategic or Co-development Partner · 1 June 2025Innovation partnership for development of personalized medications using 3D printing. CHU de Nîmes hosts the UPM (Unité de Production des Médicaments) where MB Therapeutics' industrial-grade 3D printer produces customized medications. Focus on optimizing standard oral forms for children and elderly patients.
• LynxtercoreTechnology or IntegrationOrigin partnership - Lynxter, manufacturer of industrial 3D printers, collaborated with CHU de Nîmes to create MB Therapeutics; provides underlying 3D printing technology expertise
• Université de MontpelliercoreStrategic or Co-development PartnerAcademic partnership through hosting convention initially; collaboration with Institut Charles Gerhardt de Montpellier (UM, CNRS, ENSCM) on 3DforPedia project for pediatric medication development
• Saxony (Germany) DelegationminorStrategic or Co-development PartnerFrench-German cooperation visit including State Minister Dirk Panter, Bundestag members, Fraunhofer network experts, and German Consulate General to strengthen healthcare industry ties and showcase pharmaceutical R&D
• MedValléecoreStrategic or Co-development PartnerMontpellier-based global health ecosystem partner; MB Therapeutics showcased as one of 12 companies representing MedVallée at major events including VivaTech and SantExpo
• AD'OCCcoreGTM or Marketing PartnerRegional economic development agency supporting MB Therapeutics' growth and international visibility through joint pavilion appearances at healthcare events
• BIC de MontpelliercoreStrategic or Co-development PartnerBusiness innovation center supporting MB Therapeutics as part of Montpellier's deeptech ecosystem
• Région Occitanie / Pyrénées-MéditerranéecoreGTM or Marketing PartnerRegional government partner providing pavilion space and support at major trade shows; co-funded France 2030 regional innovation project

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Triastek: Triastek is a Chinese pharmaceutical 3D printing company developing personalized oral drug formulations using proprietary MED (Melt Extrusion Deposition) technology. It is one of MB Therapeutics' closest direct competitors globally, having received FDA IND clearance for 3D-printed drugs and serving global pharma and clinical trial customers — directly comparable in technology, customer segment, and regulatory pathway.
• Aprecia Pharmaceuticals: Aprecia is the US pioneer of pharmaceutical 3D printing, with the first FDA-approved 3D-printed drug (Spritam). It competes with MB Therapeutics in producing 3D-printed personalized medicines for pharmacy and clinical use, using its proprietary ZipDose binding technology for fast-disintegrating dosage forms.
• FabRx: FabRx is a UK-based pharmaceutical 3D printing spin-out from University College London developing personalized medicines and printed drug products. It is a direct peer to MB Therapeutics in pharmaceutical 3D printing technology, target customer base (hospital and compounding pharmacies), and focus on personalized dosage forms.
• CurifyLabs: CurifyLabs is a Finnish healthtech company providing personalized medicine manufacturing solutions for compounding and hospital pharmacies, including 3D printing and automated production technology. It is a direct peer to MB Therapeutics in personalized pharmacy production, with similar GMP-compliant turnkey offerings and compounding pharmacy customer focus.

Emerging players

• Craft Health: Craft Health is a Singapore-based startup developing 3D-printed personalized medicines and supplement formulations. It is an emerging player with partial overlap to MB Therapeutics in the personalized 3D-printed medication space, though focused on a different geography and a broader supplements/pharma mix.
• Laxxon Medical: Laxxon Medical is a US/German pharmaceutical company using 3D printing technology (SPID®-Technology) to produce oral dosage forms with customized release profiles. It is an emerging player with comparable technology and customer overlap (pharmaceutical and clinical trial applications) but competes primarily in controlled-release rather than dose-customization use cases.

Regional players

• DiHeSys: DiHeSys is a German company developing 2D and 3D printing technology for personalized medicines in pharmacy settings. It is a regional European peer to MB Therapeutics, focused on personalized pharmacy production, primarily serving the German-speaking market with comparable compounding-pharmacy customer profiles.

Others

• Lynxter: Lynxter is a French industrial 3D printer manufacturer and MB Therapeutics' founding partner, providing the underlying 3D printing hardware platform. While not a direct competitor in pharmaceutical production, Lynxter is the technology origin and a key supplier/enabler of MB Therapeutics' offering.
• Fareva: Fareva is a major French CDMO where MB Therapeutics' CBO Matthieu Van Delft previously worked. As one of Europe's largest pharmaceutical contract manufacturers, Fareva represents an adjacent CDMO business model that could either partner with or compete against MB Therapeutics in pharmaceutical manufacturing services.

Broad incumbents

• Stratasys: Stratasys is a global leader in industrial 3D printing, offering polymer and desktop printing systems. As a broad incumbent in 3D printing, Stratasys provides adjacent technology and infrastructure that could be applied to pharmaceutical manufacturing, representing a potential large-scale entrant into MB Therapeutics' niche.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/mb-therapeutics
• Xx.com/mb_therapeutics
• Facebookfacebook.com/profile.php

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds1 record

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MB Therapeutics